Cost-effectiveness of febuxostat in chronic gout

European Journal of Health Economics

Volumn 15, Issue 5, 2014, Pages 453-463

  Beard, Stephen M ^a   Von Scheele, Birgitta G ^a   Nuki, George ^b   Pearson, Isobel V ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Allopurinol; Cost effectiveness; Febuxostat; Gout; Scotland

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; PLACEBO; URATE; ANTIGOUT AGENT; THIAZOLE DERIVATIVE; URIC ACID;

AGED; ARTICLE; CHRONIC DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GOUT; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; THERAPY; URIC ACID BLOOD LEVEL; VERY ELDERLY; BLOOD; COST BENEFIT ANALYSIS; DOSE RESPONSE; ECONOMICS; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCIBILITY; STATISTICAL MODEL;

COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; MARKOV CHAINS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; THIAZOLES; URIC ACID;

EID: 84905700381     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-013-0486-z     Document Type: Article

References (50)

1. Roddy, E., Zhang, W., Doherty, M.: Is gout associated with reduced quality of life? A case-control study. Rheumatology (Oxford) 46, 1441-1444 (2007)
2. Khanna, D., Ahmed, M., Yontz, D., et al.: The disutility of chronic gout. Qual. Life Res. 17, 815-822 (2008)
3. Singh, J.A., Strand, V.: Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans. Ann. Rheum. Dis. 67, 1310-1316 (2008)
4. Becker, M.A., Schumacher, H.R., Benjamin, K.L., et al.: Quality of life and disability in patients with treatment-failure gout. J. Rheumatol. 36, 1041-1048 (2009)
5. Kleinman, N.L., Brook, R.A., Patel, P.A., et al.: The impact of gout on work absence and productivity. Value Health 10, 231-237 (2007)
6. Halpern, R., Fuldeore, M.J., Mody, R.R., et al.: The effect of serum urate on gout flares and their associated costs: an administrative claims analysis. J Clin Rheumatol 15(1), 3-7 (2009)
7. Wu, E.Q., Patel, P.A., Mody, R.R., et al.: Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter? J. Rheumatol. 36, 1032-1040 (2009)
8. Brook, R.A., Kleinman, N.L., Patel, P.A., et al.: The economic burden of gout on an employed population. Curr. Med. Res. Opin. 22, 1381-1389 (2006)
9. Wu, E.Q., Patel, P.A., Yu, A.P., et al.: Disease-related and allcause health care costs of elderly patients with gout. J Manag Care Pharm. 14, 164-175 (2008)
10. Hanly, J.G., Skedgel, C., Sketris, I., et al.: Gout in the elderly - a population health study. J. Rheumatol. 36, 822-830 (2009)
11. Annemans, L., Spaepen, E., Gaskin, M., et al.: Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann. Rheum. Dis. 67, 960-966 (2008)
12. Mikuls, T.R., Farrar, J.T., Bilker, W.B., et al.: Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Ann. Rheum. Dis. 64, 267-272 (2005)
13. Li-Yu, J., Clayburne, G., Sieck, M., et al.: Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J. Rheumatol. 28, 577-580 (2001)
14. Shoji, A., Yamanaka, H., Kamatani, N.: A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 51, 321-325 (2004)
15. Perez-Ruiz, F.: Treating to target: a strategy to cure gout. Rheumatology (Oxford) 48(suppl 2), ii9-ii14 (2009)
16. Zhang, W., Doherty, M., Bardin, T., et al.: EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann. Rheum. Dis. 65, 1312-1324 (2006)
17. Jordan, K.M., Cameron, J.S., Snaith, M., et al.: British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46, 1372-1374 (2007)
18. Cegedim Strategic Data UK Ltd.: Data on File. (2010)
19. A. Menarini Pharma UK SRL: Adenuric Film-Coated Tablets. Summary of Product Characteristics. 12 May 2011. http://www.medicines.org.uk/emc/document. aspx?documentId=22830#CLINICAL-PARTS. Date last accessed 3 Nov 2011
20. National Institute for Health and Clinical Excellence: Final Appraisal Determination. Febuxostat for the Management of Hyperuricaemia in People with Gout NICE. Aug 2008. http://www.nice.org.uk/nicemedia/live/11830/41648/41648. pdf. Date last accessed 3 Nov 2011
21. Scottish Medicines Consortium: Febuxostat 80 mg and 120 mg Tablets (Adenuric®) SMC No. 637/10. 6 Aug 2010. http://www.scottishmedicines.org.uk/ files/advice/febuxostat-Adenuric-FINAL-August-2010.pdf. Date last accessed 3 Nov 2011
22. Schumacher Jr, H.R., Becker, M.A., Wortmann, R.L., et al.: Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 59, 1540-1548 (2008)
23. Becker, M.A., Schumacher Jr, H.R., Wortmann, R.L., et al.: Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N. Engl. J. Med. 353, 2450-2461 (2005)
24. Becker, M.A., Schumacher, H.R., MacDonald, P.A., et al.: Clinical efficacy and safety of successful long-term urate lowering with febuxostat or allopurinol in subjects with gout. J. Rheumatol. 36, 1273-1282 (2009)
25. Becker, M.A., Schumacher, H.R., Espinoza, L.R., et al.: The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial. Arthritis Res Ther 12, R63 (2010). doi:10.1186/ar2978
26. Schumacher Jr, H.R., Becker, M.A., Lloyd, E., et al.: Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford) 48, 188-194 (2009)
27. Becker, M.A., Schumacher Jr, H.R., Wortmann, R.L., et al.: Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 52, 916-923 (2005)
28. Ipsen, U.K.: Integrated Summary of Efficacy. Data on File. (2005)
29. Institute of Medical Science World Publications Ltd: A Health Economic Assessment of Febuxostat in the Management of Gout. Data on File. Version No. 1.0, 19 Oct 2007
30. BMJ Publishing Group Ltd., RCPCH Publications Ltd., Royal Pharmaceutical Society of Great Britain: British National Formulary. http://bnf.org/bnf/bnf/ current/index.htm. (2011)
31. Office for National Statistics: Mortality Statistics. Deaths Registered in 2007
32. Scottish Medicines Consortium: Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF). June 2011. http://www.scottishmedicines. org.uk/files/submissionprocess/New-Product-Assessment-Form-NPAF-Guidance-Notes- updated-February-2011-Final.doc. Date last accessed 3 Nov 2011
33. Roddy, E., Zhang, W., Doherty, M.: Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations. Ann. Rheum. Dis. 66, 1311-1315 (2007)
34. National Institute for Health and Clinical Excellence: Guide to the Methods of Technology Appraisal. June 2008. http://www.nice.org.uk/media/B52/A7/ TAMethodsGuideUpdatedJune2008.pdf Date last accessed 3 Nov 2011
35. Borstad, G.C., Bryant, L.R., Abel, M.P., et al.: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J. Rheumatol. 31(12), 2429-2432 (2004)
36. Ipsen, U.K.: Febuxostat for the Treatment of Gout Single Technology Appraisal Submission to the National Institute for Health and Clinical Excellence. 14 May 2008. http://www.nice.org.uk/nicemedia/live/11830/40731/ 40731.pdf. Date last accessed 3 Nov 2011
37. Jackson, T.: Cost Analysis of Febuxostat Versus Allopurinol for Prophylaxis of Gout Flares. In: Poster presented at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research. Washington, DC, June 2-6 2012
38. Jutkowitz, E., Pizzi, L., Meltzer, M.: Comparison of cost of allopurinol vs febuxostat as a first line treatment for gout. Value Health 13(3), A123 (2010)
39. Pandya, B.J., Quimbo, R.A., Mody, R., et al.: Budgetary impact of a new urate-lowering therapy (ULT) for the treatment of gout in a US health plan formulary. Value Health 12(7), A435 (2009)
40. Rashid, N., Hay, J.W.: Cost effectiveness analysis of managing chronic gout with febuxostat (Uloric) versus allopurinol (Zyloprim). Value Health 13(3), A126 (2010)
41. Redding, L., Hornberger, J., Cowens, W., et al.: Cost-effectiveness of febuxostat in managing hyperuricemia in gout patients in Canada. J Popul Ther Clin Pharmacol 18(2), e195-e196 (2011)
42. Stevenson, M., Pandor, A.: Hyperuricaemia - febuxostat: Evidence Review Group Report. Febuxostat for the Management of Hyperuricaemia in Patients with Gout. 31 March 2008. http://www.nice.org.uk/nicemedia/live/11830/40721/40721. pdf. Date last accessed 3 Nov 2011
43. Stevenson, M., Pandor, A.: Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. Health Technol. Assess. 13(suppl 3), 37-42 (2009). http://www.hta.ac.uk/erg/supplements/supplement1303. pdf#nameddest=article06. Date last accessed 3 Nov 2011
44. Stevenson, M., Pandor, A.: Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics 29(2), 133-140 (2011). http://www.ncbi.nlm.nih.gov/pubmed/ 21155617. Date last accessed 3 Nov 2011
45. Reinders, M.K., Haagsma, C., Jansen, T.L., et al.: A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout. Ann. Rheum. Dis. 68, 892-897 (2009)
46. Lee, S.J., Hirsch, J.D., Terkeltaub, R., et al.: Perceptions of disease and health-related quality of life among patients with gout. Rheumatology (Oxford) 48, 582-586 (2009)
47. van Groen, M.M., ten Klooster, P.M., Taal, E., et al.: Application of the health assessment questionnaire disability index to various rheumatic diseases. Qual. Life Res. 19, 1255-1263 (2010)
48. Dalbeth, N., Collis, J., Gregory, K., et al.: Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford) 46, 1804-1807 (2007)
49. Teng, G.G., Nair, R., Saag, K.G.: Pathophysiology, clinical presentation and treatment of gout. Drugs 66, 1547-1563 (2006)
50. Niskanen, L.K., Laaksonen, D.E., Nyyssonen, K., et al.: Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch. Intern. Med. 164, 1546-1551 (2004)